Skip to main content
Premium Trial:

Request an Annual Quote

Sciona Relocates from UK to Colorado, Hires New CEO

NEW YORK, Jan. 25 (GenomeWeb News) - Sciona, a privately held firm developing DNA screens for nutrigenomics applications, has moved its headquarters from Havant, UK, to Boulder, Colo., the company said today.

 

Sciona has also appointed a new CEO, James Bruce, who most recently served as president and CEO of Madaus, a nutraceutical company.

 

The company's former CEO, Chris Martin, is now chairman of the board. He will continue to reside in the UK.

 

Sciona said it will employ a dozen people in Boulder and additional staff elsewhere in the UK, Italy, and the US, including an R&D lab on the YaleUniversity campus. Several of Sciona's UK employees will relocate to Boulder, including CTO Rosalynn Gill-Garrison, who will lead R&D activities.

 

Sciona currently markets the Cellf genetic screen, which provides nutritional guidelines for consumers based on their genetic profiles. The company also sells genetic screens in the areas of heart health, bone health, antioxidants and detoxification, immune response, and insulin sensitivity.

The Scan

Genes Linked to White-Tailed Jackrabbits' Winter Coat Color Change

Climate change, the researchers noted in Science, may lead to camouflage mismatch and increase predation of white-tailed jackrabbits.

Adenine Base Editor Targets SCID Mutation in New Study

Researchers from the University of California, Los Angeles, report in Cell that adenine base editing was able to produce functional T lymphocytes in a model of severe combined immune deficiency.

Researchers Find Gene Affecting Alkaline Sensitivity in Plants

Researchers from the Chinese Academy of Science have found a locus affecting alkaline-salinity sensitivity, which could aid in efforts to improve crop productivity, as they report in Science.

International Team Proposes Checklist for Returning Genomic Research Results

Researchers in the European Journal of Human Genetics present a checklist to guide the return of genomic research results to study participants.